Dear Clients and Partners, As the year draws to a close, we’d like to take the opportunity to focus on some key recent developments. 2013 has been a year of partnerships: From our very productive continuing collaboration with Prof. Jessica Houston at New Mexico State University, to our expanded relationship with great…

It's been a busy summer. In several instances over the last couple of months I have been honored with invitations to participate and contribute to events relevant to the life sciences / biophotonics / medical device communities. Here are the upcoming opportunities to hear first-hand what Kinetic River is up…

CYTO 2013 (XXVIII Congress of the International Society for Advancement of Cytometry), the annual “watering-hole” gathering for cytometrists of all shapes and sizes, took place in San Diego this year, and it was exciting as ever. The scientific program turned up a number of interesting new research results, and the trade…

Recently I've had the chance to hear a thought-provoking lecture by Paul Yock, Professor of Medicine and Director of Biodesign at Stanford University, at the 10th anniversary of the founding of the Bio2Device Group. Dr. Yock spoke about the global evolution of medical device innovation, focusing in particular on the example…

While this is not exactly the typical required experience you find in high-tech job descriptions, the point is that to learn how to make tires screech, you’ve already had to master a delicate balance between energy storage and energy dissipation. And that’s the key principle on which a special kind*…

Time-resolved flow cytometry enables cell biologists to study proteins and cellular microenvironment San Francisco, Calif., USA, February 3, 2013 – Kinetic River Corp., a leader in flow cytometry instrumentation design and product development, officially launched the Danube today at Photonics West’s BiOS Expo in San Francisco, Calif. Under development since early 2012, the Danube goes…

Personalized medicine seems all the buzz these days. People talk about things like whole-genome analysis to determine individual propensity towards specific disease states, or the development of drugs tailored to be maximally effective, and minimally side-effective, for certain narrowly defined patient sub-populations. Major scientific advances along these and other lines…